Pharma BD Deal Intelligence
Roche acquired IGEN International for approximately $1.4 billion ($47.25 per share plus a share in the newly spun-off BioVeris), securing perpetual worldwide rights to IGEN's electrochemiluminescence (ECL) technology underpinning its Elecsys diagnostics line. The transaction resolved a long-running ECL license dispute that had produced a major jury verdict against Roche. Announced July 2003 and closed in mid-February 2004.